Show results for
Refine by
Development And Clinical Services In Germany
17 services found
Manufactured by:IDT Biologika based inDessau-Rosslau, GERMANY
IDT Biologika is one of the world’s most experienced CDMOs in terms of expertise in developing and manufacturing of Viral Vaccines, Viral Vectors for Gene and Immune Therapeutics, Oncolytic Viruses, Virus-Like Particles, and other Biologics. We have GMP manufacturing facilities in Europe and the United States, offering capabilities from early-stage ...
by:IBA based inLouvain-La-Neuve, BELGIUM
IBA takes a hands-on approach during the ramp up phase and uses our past experiences with our numerous clinical centers to develop a dedicated support program for the ramp up phase. This includes: patient recruitment help, national marketing package, additional education of referrers, collaboration with existing IBA centers for QA validation, and quality system ...
by:Eurofins bioskin ( formely Bioskin GmbH) based inHamburg, GERMANY
The regulatory pathway for dermatological products, in particular topically applied products, differs from those for other therapeutic indications and dosage forms. Various options of proof-of-concept designs will help you move your development programs into the best direction. Early development of proper strategies shortens timelines and reduces costs. ...
Manufactured by:RfQ-Medizintechnik GmbH & Co. KG based inTuttlingen, GERMANY
RfQ has created the conditions required to implement the visions of our clients in efficient series products after many years growing development expertise. The use of new materials and the development of processes and techniques involved, are based on the close communication and teamwork with our customers and reputable clinics and medical ...
by:Vetter based inRavensburg, GERMANY
Our experts provide the guidance, insight, and Vetter process documentation you need to prepare a Common Technical Document (CTD) for clinical trials of your injectable drug ...
Manufactured by:Sartorius AG based inGoettingen, GERMANY
A more seamless transition into the clinic. Complex biopharmaceuticals and advanced therapies can present challenges during preclinical development. When implementing an albumin-based solution, Albumedix can help avoid unnecessary complications in your preclinical testing by creating species-specific recombinant albumins to suit your preclinical models. ...
Manufactured by:MediTECH Electronic GmbH based inWedemark, GERMANY
The decision on whether a person has ADHD/ADHD has so far been based mainly on questionnaires and behavioural observation. Both methods are highly subjective. In cooperation with the Charité Berlin and the University Clinic Mainz, MediTECH has developed a new objective measurement procedure for the determination / exclusion of ...
by:M3i GmbH based inMunich, GERMANY
Clinical expertise for medical AI: Passionate about outstanding medical AI; Enable the full potential of AI in healthcare through a structured development process from clinical data acquisition to regulatory approval. We offer “gold standard” training datasets, high-quality annotations and feedback of clinical experts ...
by:Indivumed GmbH based inHamburg, GERMANY
Biomarkers are important when it comes to the development of novel drugs and mechanisms and are also gaining importance as companion diagnostic ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Graft Versus Host Disease (GvHD) is a potentially lethal complication of hematopoietic cell transplantation (HCT) from a donor. When a patient receives a donor’s stem cells, the transplanted cells may identify the patient’s body as foreign and attack it. The chronic form of GvHD occurs at least 100 days following the transplantation. The GvHD market is predicted to exceed $500 million ...
Manufactured by:Atriva Therapeutics GmbH based inTübingen, GERMANY
The company’s lead drug candidate is the MEK inhibitor zapnometinib. The small molecule, which can be administered orally (tablet), is under advanced clinical development in two severe respiratory viral diseases: COVID-19 and influenza, two disease areas with urgent need for effective ...
by:Vetter based inRavensburg, GERMANY
Explore how we transform your API into a supply of high-quality clinical material for your ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Pluristem’s goal is to provide patients, physicians and healthcare systems around the globe with standardized, easy to use and highly effective PLX cell products that need no genetic or tissue matching prior to administration. We are active with many respectful regulatory agencies worldwide to advance our clinical programs towards marketing. Part of our ...
by:Revvity Gene Delivery (formerly SIRION Biotech) based inHamburg, GERMANY
In the discovery of oncology therapeutics, Antibody-drug conjugates (ADCs) are rapidly gaining momentum, with hundreds of candidates advancing through clinical development. Whether your priority lies in assessing the epitope binding of your construct, evaluating the cytotoxic potency of the payload, or scrutinizing the efficacy of the linker in cleaving, each ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
COVID-19 is caused by infection with the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may cause clusters of severe respiratory illness associated with the need for intensive care unit (ICU) admission and high mortality. Studies have shown that Acute Respiratory Distress Syndrome (ARDS) following viral pneumonia is one of the most common causes of death from ...
by:PharmaLex GMBH based inFriedrichsdorf, GERMANY
The Global Statistics and Data Science (GSDS) team at PharmaLex delivers analytical support for the development of medical products–from early research through pre-clinical to late phase studies, plus manufacturing and health economics. We support our clients every step of the way–from discovery and non-clinical requirements to early ...
Manufactured by:Pluristem Therapeutics Inc. based inHaifa, ISRAEL
Femoral neck fracture is the most common form of hip fracture with annual treatment costs in the U.S. estimated to be between $10 to $15 billion, and are expected to rise due to the aging population, with mortality rates of up to 36%. *click for further information about Muscle injury due to total hip ...